Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate vs Risperidone LAI in Schizophrenia
NCT00604279Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2008
- Primary completion
- Jan 2009
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Jan 2008; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00604279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604279.